From the Food and Drug Administration.
Schwetz
B A
BA
Acting Principal Deputy Commissioner, Food and Drug Administration, USA.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004051:Diethylhexyl Phthalate / Q000009:adverse effects*; D000077143:Docetaxel; D005260:Female; D005380:Financing, Government; D005472:Fluorouracil / Q000031:analogs & derivatives; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D008297:Male; D009965:Orphan Drug Production; D010138:Pacemaker, Artificial; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013091:Spermatogenesis / Q000187:drug effects; D043823:Taxoids; D013737:Testis / Q000187:drug effects; D014481:United States; D014486:United States Food and Drug Administration
D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D004051:Diethylhexyl Phthalate; D017239:Paclitaxel; D005472:Fluorouracil